Can a monthly injection replace blood thinners for stroke prevention?

NCT ID NCT07739888

First seen Jul 31, 2026 ยท Last updated Jul 31, 2026

Summary

This phase 3 trial is testing an investigational drug called abelacimab in about 2,500 people with atrial fibrillation (an irregular heartbeat) who are at high risk for stroke but cannot take standard oral blood thinners. Participants will receive either abelacimab or a placebo, and researchers will track how well it prevents strokes and blood clots, as well as any bleeding side effects. The goal is to see if this injectable treatment offers a safer or more effective option for stroke prevention in this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
abelacimab (an investigational injectable anticoagulant)
What this could lead to
If successful, abelacimab could offer a new way to prevent strokes in people with atrial fibrillation who cannot use standard oral blood thinners, potentially reducing their risk of life-threatening blood clots.
What could go wrong
This is a large phase 3 trial, but the drug is still investigational. The main risk is bleeding, which could be serious. It may not prove safer or more effective than existing options, and results are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.